BidaskClub lowered shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

A number of other brokerages have also commented on AIMT. ValuEngine upgraded Aimmune Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, October 17th. Wedbush set a $80.00 price target on Aimmune Therapeutics and gave the company a buy rating in a report on Monday, November 12th. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the company a buy rating in a report on Tuesday, October 9th. Cantor Fitzgerald started coverage on Aimmune Therapeutics in a report on Sunday, December 2nd. They issued a buy rating and a $64.00 price target on the stock. Finally, Credit Suisse Group set a $40.00 price target on Aimmune Therapeutics and gave the company a buy rating in a report on Friday, November 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $51.70.

AIMT stock opened at $23.06 on Tuesday. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -8.84 and a beta of -0.13. Aimmune Therapeutics has a 1-year low of $21.47 and a 1-year high of $42.00.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.03. On average, equities analysts predict that Aimmune Therapeutics will post -3.55 EPS for the current year.

In related news, insider Jayson Donald Alexander Dallas bought 3,650 shares of the company’s stock in a transaction that occurred on Monday, November 19th. The shares were acquired at an average price of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the acquisition, the insider now owns 63,600 shares of the company’s stock, valued at approximately $1,752,816. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 24.56% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AIMT. Janney Montgomery Scott LLC raised its holdings in Aimmune Therapeutics by 27.8% during the second quarter. Janney Montgomery Scott LLC now owns 14,720 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 3,200 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Aimmune Therapeutics by 16.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 260,435 shares of the biotechnology company’s stock worth $7,003,000 after acquiring an additional 37,053 shares in the last quarter. TD Asset Management Inc. raised its holdings in Aimmune Therapeutics by 2.4% during the second quarter. TD Asset Management Inc. now owns 88,927 shares of the biotechnology company’s stock worth $2,391,000 after acquiring an additional 2,100 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in Aimmune Therapeutics by 134.0% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 75,125 shares of the biotechnology company’s stock worth $2,020,000 after acquiring an additional 43,020 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Aimmune Therapeutics by 3.3% during the second quarter. Victory Capital Management Inc. now owns 686,481 shares of the biotechnology company’s stock worth $18,460,000 after acquiring an additional 21,840 shares in the last quarter. Institutional investors and hedge funds own 75.04% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Read More: What factors cause inflation to rise?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.